Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 4Carcinoma, Adenoid Cystic 2Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1Down Syndrome 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Epirubicin 2pembrolizumab 1lenvatinib 1enfortumab vedotin 1anlotinib 1amivantamab 1Pemetrexed 1Observation 1Ipilimumab 1Imatinib Mesylate 1Glutamate Carboxypeptidase II 1Cyclophosphamide 1CTLA-4 Antigen 1Blood Specimen Collection 1BMS-906024 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Adenoid Cystic × Epirubicin × 90 days × Clear all
NCT07616141 2026-06-01

NAET4-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Not yet recruiting
76 enrolled

Carcinoma, Adenoid Cystic

NCT07320508 2026-05-12

EIC-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Recruiting
100 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡